



HAL
open science

Single-cell differentiation trajectories define early stages of a human cutaneous T-cell lymphoma

Juan-pablo Cerapio, Marion Perrier, Frédéric Pont, Camille Laurent,
Stephane Bertani, Jean-jacques Fournie

► **To cite this version:**

Juan-pablo Cerapio, Marion Perrier, Frédéric Pont, Camille Laurent, Stephane Bertani, et al.. Single-cell differentiation trajectories define early stages of a human cutaneous T-cell lymphoma. *Exploration of Immunology*, 2022, pp.185 - 199. 10.37349/ei.2022.00044 . hal-03654808

HAL Id: hal-03654808

<https://hal.science/hal-03654808v1>







Submitted on 28 Apr 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Single-cell differentiation trajectories define early stages of a human cutaneous T-cell lymphoma

Juan-Pablo Cerapio^{1,2,3,4,5*}, Marion Perrier^{1,2,3,4,5}, Frédéric Pont^{1,2,3,4,5}, Camille Laurent^{1,2,3,4,5,6,7}, Stéphane Bertani^{2,8,9}, Jean-Jacques Fournie^{1,2,3,4,5,6,10*}

¹Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, Toulouse 31037, France

²Toulouse University, Toulouse 31037, France

³CNRS UMR 5071, Toulouse 31037, France

⁴Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse 31037, France

⁵Laboratoire d'Excellence 'TOUCAN-2', Toulouse 31037, France

⁶Institut Carnot Lymphome CALYM, Toulouse 31037, France

⁷Centre Hospitalier Universitaire, Toulouse 31037, France

⁸Pharmadev, IRD UMR 152, Toulouse 31037, France

⁹International Joint Laboratory of Molecular Anthropological Oncology (LOAM), IRD-INEN, Lima, Peru

¹⁰Lead Contact

***Correspondence:** Juan-Pablo Cerapio, Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, Toulouse 31037, France; Toulouse University, Toulouse 31037, France; CNRS UMR 5071, Toulouse 31037, France; Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse 31037, France; Laboratoire d'Excellence 'TOUCAN-2', Toulouse 31037, France. juan-pablo.cerapio-arroyo@inserm.fr; Jean-Jacques Fournie, Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, Toulouse 31037, France; Toulouse University, Toulouse 31037, France; CNRS UMR 5071, Toulouse 31037, France; Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse 31037, France; Laboratoire d'Excellence 'TOUCAN-2', Toulouse 31037, France; Institut Carnot Lymphome CALYM, Toulouse 31037, France; Lead Contact. Jean-jacques.fournie@inserm.fr

Academic Editor: Dieter Kabelitz, Christian-Albrechts University of Kiel and University Hospital Schleswig-Holstein Campus Kiel, Germany

Received: December 22, 2021 **Accepted:** March 8, 2022 **Published:** April 15, 2022

Cite this article: Cerapio JP, Perrier M, Pont F, Laurent C, Bertani S, Fournie JJ. Single-cell differentiation trajectories define early stages of a human cutaneous T-cell lymphoma. *Explor Immunol.* 2022;2:185–99. <https://doi.org/10.37349/ei.2022.00044>

Abstract

Aim: The aim of this article is to characterize in detail the $\gamma\delta$ T lymphocytes from an adult patient with primary cutaneous T-cell lymphoma of $\gamma\delta$ subtype ($\gamma\delta$ CTCL).

Methods: Here this article reports trajectory mapping on high-resolution differentiation trajectories of $\gamma\delta$ T lymphocytes digitally extracted from a scRNAseq dataset.

Results: In the patch-to-plaque progression of CTCL, the TCRV γ non9 subset of $\gamma\delta$ T cells differentiated from naive T cells (T_n) and central memory T cells (T_{cm}) to abundant effector memory T cells (T_{em}) while other cutaneous $\gamma\delta$ T and CD8 T cells remained unchanged.

Conclusions: This transcriptomic switch underlies the emergence of a CTCL-like progression of the TCRV γ non9 $\gamma\delta$ T subtype and suggests new routes for treating these diseases.

Keywords

Gamma delta lymphoma, scRNAseq, differentiation, trajectory

© The Author(s) 2022. This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.



Introduction

The $\gamma\delta$ T lymphocytes contribute to both innate and adaptive immunity, notably against viral infections and cancers. Human $\gamma\delta$ T cells are CD3⁺CD4⁻CD8⁻ lymphocytes whose cell surface T-cell receptor (TCR) is composed either of T-cell receptor variable chain $\gamma 9$ (TCRV $\gamma 9$) prominently paired with TCRV $\delta 2$, or TCRV γ non9 (TCRV $\gamma 2/3/4/5/8$) paired with any of the TCRV $\delta 1, 2, 3$ chains. The TCRV $\gamma 9$ V $\delta 2$ cells represent the prominent subset of $\gamma\delta$ T cells in circulating blood, while the TCRV γ non9 cells dominate in the skin, mucosae, and non-lymphoid tissues. Furthermore, the TCRV $\gamma 9$ V $\delta 2$ $\gamma\delta$ T lymphocytes are specific for phosphoantigen-induced butyrophilin complexes while TCRV γ non9 $\gamma\delta$ T cells recognize more diversified antigens. The functional profile of all the $\gamma\delta$ T lymphocytes depends on their differentiation stage, encompassing naive T cells (Tn), central memory T cells (Tcm), effector memory T cells (Tem), and terminally differentiated CD45Ra⁺ Tem (Temra) cells. When stimulated, the Tn cells can only proliferate and differentiate into Tcm, which are endowed with similar functions plus migratory but not cytokine activity, and then into Tem cells with potent cytokine and cytotoxic functions, and finally into the highly cytotoxic Temra cells.

Using single-cell RNA sequencing (scRNAseq), we previously showed that this linear differentiation presents similar dynamics in both TCRV $\gamma 9$ and TCRV γ non9 subsets of human $\gamma\delta$ T cells [1]. We further refined the transcriptomic transitions underlying this differentiation by delineating 14 successive milestones from the Tn to Temra cells as visualized in a pseudotime-based trajectory [2]. The differentiation stages of $\gamma\delta$ T lymphocytes in patients with cancers or with coronavirus disease 2019 (COVID-19) were characterized accordingly and unveiled the association of circulating $\gamma\delta$ T lymphocytes with the viral status of individuals [3]. These studies illustrated the power and resolution achieved by trajectory mapping for normal $\gamma\delta$ T lymphocytes, but its potential for characterizing the differentiation of malignant $\gamma\delta$ T cells was unknown.

The $\gamma\delta$ T lymphocytes represent the cell-of-origin for some cutaneous T-cell lymphoma (CTCL), a subtype of skin-homing T cells malignancy named $\gamma\delta$ CTCL [4–8]. In their early stages, CTCL may arise as cutaneous lesions termed mycosis fungoides (MF) where long-lasting skin patches homing abundant T cell infiltrates eventually switch by unknown mechanisms to thicker skin plaques and may evolve further to a disseminated T cell lymphoma. More specifically, MF represents a malignancy of skin resident T cells at the Tem differentiation stage, while leukemic CTCL is rather a malignancy of recirculating Tcm lymphocytes [9]. To explore the mechanisms of this early progression, here we digitally extracted the $\gamma\delta$ T lymphocytes from a recently published scRNAseq dataset of $\gamma\delta$ CTCL [10] with patch and plaque annotations (MF318 from GSE173205), and analyzed these cells by ‘trajectory mapping’. The findings we report from this new type of data exploration provide novel insight into the cellular mechanisms underlying the early stages of this T cell malignancy.

Materials and methods

scRNAseq datasets, pre-processing, and reference trajectory

A series of scRNAseq datasets from ~150 healthy individuals and cancer patients’ samples were downloaded from Gene Expression Omnibus (GEO, <https://www.ncbi.nlm.nih.gov/geo>) integrated and preprocessed as one single reference dataset as depicted [2]. Briefly, the sequencing output bcl2 files were converted to FASTQ format by using cellranger-mkfastq™ algorithm (10× Genomics), and cellranger-count was applied to align to the GRCh38 reference transcriptome and build the (cell, UMI) expression matrix for each sample. Preprocessing, normalization of UMI, and QC were assessed using the R package Seurat 3.0 [11]. First, genes that correspond to human leukocyte antigens (HLA) and genes located in chromosomes X and Y were removed, and the quality of cells was then determined by the number of detected genes per cell and the proportion of mitochondrial genes. The datasets were normalized together and variable features from each dataset were identified by FinVariable-Data before identification of anchors correspondences across all the datasets, to yield an integrated dataset. Principal components analysis (PCA) was then performed on this integrated dataset before dimensionality reduction by uniform manifold approximation and projection (UMAP) [12]. All its single cells were then scored for various multigene signatures, to further perform the digital extraction of $\gamma\delta$ T and of CD8 T lymphocytes by score and gate [2]. An unbiased differentiation

trajectory of these $\gamma\delta$ T lymphocytes was computed without prior information by a minimum spanning tree (MST) algorithm to determine each $\gamma\delta$ T cell's position, pseudotime, and milestone. The reference $\gamma\delta$ T cells matrix (cell, gene, pseudotime, and other hallmarks) is published elsewhere [2]. This reference $\gamma\delta$ T cell trajectory was visualized as a pseudotimed plot featuring every single cell by its pseudotime (x -axis) vs. its MST1 and MST2 dimensions projection (y -axis) [2]. For clarity, this reference trajectory is shown as a grey cells background onto which additional $\gamma\delta$ T cells, here from the CTCL patient, were mapped. The same pipeline was applied for CD8 T cells whenever mentioned in the text.

In parallel, the $\gamma\delta$ T and CD8 T cells were extracted likewise from the CTCL patient MF318 scRNAseq dataset, downloaded from the publicly available GEO GSE173205 [10]. This dataset was separately pre-processed by using the same Seurat 3.0 pipeline, and its single cells were scored for multigene signatures to further digitally extract its $\gamma\delta$ T and CD8 T lymphocytes by score and gate as above. Before injection into the reference dataset (see below), the $\gamma\delta$ T and CD8 T lymphocytes extracted from this CTCL dataset are referred to as '*ab extra*' cells.

Injection of *ab extra* $\gamma\delta$ T cells on the public $\gamma\delta$ T cell differentiation trajectory

Since the differentiation trajectory of N cells is computed from their N transcriptomes, the resulting trajectory varies with N. As a consequence, adding any newer dataset of *ab extra* cells (e.g., 'M cells') to a previous 'N cells' dataset creates a newer ('N + M cells') dataset which trajectory differs from the former one. Here, we aimed at freezing the 'N cells' trajectory such as to keep it as a stable reference when adding *ab extra* cells and identify their hallmarks by their position on this reference.

We incepted and applied 'single-cell injector', a two-step procedure based on Seurat's anchoring integration function [11] (Figure S1). The single-cell injector integrates as described [11] a new dataset (named 'Query') into a reference dataset (named 'reference') in which cells coordinates are already annotated (cells, cluster, t -SNE, UMAP, trajectory, milestone, pseudotime). The resulting dataset ('Query 2') is then used by Seurat's function MapQuery to anchor Query 2 in the reference as already published [11]. Because pseudotime and milestones are already known in the reference, the N 'auto' anchors of the reference's N cells to themselves allow to precisely determine the pseudotime and milestone attributes of each Query's single cell, without change to the reference trajectory. The injector procedure was validated using the $\gamma\delta$ T cell reference dataset since it comprises cells whose MST1, MST2, milestones, and pseudotime are already known. So, $n = 7,449$ $\gamma\delta$ T cells randomly selected from this reference were used as a Query, and this Query was injected into the reference by the depicted procedure. For each Query cell, the injected position and initial position were compared, using as a metric the Euclidian distance (Δ) between the injected and the initial (MST1, MST2) coordinates. With maximally wrong injections such tests could theoretically lead to $\Delta_{\max} = 91$. However, the distribution of each Query cell's Δ revealed 87% perfect injection ($n = 6,512$ cells injected at $\Delta = 0$) and 13% injected close to the expected position ($n = 935$ cells injected at $\Delta < 15$, all of which for cells from the M5–M8 branching milestones) (Figure S1b). These results validated the *ab extra* cell injector procedure, so the CTCL derived $\gamma\delta$ T lymphocytes were injected likewise in the reference and their respective pseudotimes and milestones were determined accordingly (Tables S1 and S2). When mentioned in the text, the same pipeline was applied to the CTCL-derived CD8 T cells.

Differential pathway/signature analysis

Pathway enrichment analysis was performed using Single-Cell Signature Explorer function scorer [13] to score all the signatures from the MSigDB (<http://www.gsea-msigdb.org>) collections Kyoto Encyclopedia of Genes and Genomes (KEGG), GO-MF, GO-BP, Reactome, hallmarks, C6, and C7. These genesets were scored in each single $\gamma\delta$ T cell of the specified subset from the reference's healthy donors [2] and from the patch or plaque samples. Each score was compared between the specified CTCL and healthy cell groups by using unpaired Student's t and Bonferroni correction false discovery rate (FDR). Plots of representative differential pathways were produced by using the R package pathfindR.

Cell classifications

Cell classifications of differentiation stage were based on their respective milestones as Tn (M1, M2), Tcm (M3–7), Tem (M8–13), and Temra (M13, 14) (Figure 1). Since $\gamma\delta$ T lymphocytes express either the *TRGC1*-encoded TCRV γ 9 or the *TRGC2*-encoded TCRV γ non9 in a mutually exclusive fashion, subtyping of the TCRV γ 9 and TCRV γ non9 $\gamma\delta$ T cells was performed by plots of compensated scores of the signatures ('*TRDC*, *TRGC1*' positive cells) vs. ('*TRDC*, *TRGC2*' positive cells) [2]. The cell classifications as tissue resident memory T cell (Ttrm)/recirculating (non-Ttrm) and exhausted T cell (Tex)/functional (non-*Tex*) were performed by 'at least one binary' as follows. The single cells were scored for several reference gene signatures (Table S1). For *Tex* classification, the reference *Tex* signatures were as published [14–18]. For each signature, a cut-off was defined as the maximal score of the ($n = 3,680$) control $\gamma\delta$ T or CD8 T lymphocytes extracted from healthy adults peripheral blood mononuclear cell (PBMC). This threshold defined the cell's binary (1 for cell score > threshold, 0 otherwise). The *Tex* cut-offs were: 3.9 for 'Chihara_IL27_Coinhib_module' [14]; 0.52 for 'Alfei_d20_tox' [15]; 0.22 for 'Khan_Tox_OverExpressed_genes' [16]; 0.5 for 'Tosolini_NHL_IEGS33' [17]; and 0.16 for 'Balanca_QP_genes' [18]. For each tumor-infiltrating lymphocyte (TIL), the five *Tex* binaries were summed, and any TIL with a non-zero-sum of binaries was classified *Tex*, or non-*Tex* otherwise. The Ttrm classification was applied likewise using Ttrm signatures from the literature [19, 20]. The binarizing cutoffs established with the control CD8 T lymphocytes were: 0.46 for 'Kumar_13g_Ttrm'; 0.3 for 'Kumar_3g_Ttrm' [19]; 3.72 for 'Wu_Tcellcluster4.1_trm'; 2.6 for 'Wu_Tcellcluster8.3_trm'; 2.8 for 'Wu_Tcellcluster8.3b_trm'; 4.2 for 'Wu_Tcellcluster8.3c_trm' [20]. These Ttrm binaries were summed, and any TIL with a non-zero-sum of Ttrm binaries was classified Ttrm, or non-Ttrm (recirculating) otherwise.




Figure 1. Differentiation trajectory, UMAP, and marker genes of reference and CTCL patient $\gamma\delta$ T cells. a). Differentiation trajectory of all $\gamma\delta$ T cells digitally extracted from the reference and dataset of MF318 patient skin is shown with the corresponding reference trajectory milestones. Differentiation pseudotime scale: 0–5 for Tn, 5–20 for Tcm, 20–48 for Tem; 48–55 for Temra. UMAP of the same cells featuring b). the above milestones (same color key as a); or c). their pseudotime; d). UMAP of $\gamma\delta$ T cells extracted from the CTCL patient specifying the TCRV γ subtype overlaid to the reference cells (grey); e). mean and percentage of marker gene expression level per milestones

Results

Extraction and integration of skin $\gamma\delta$ T lymphocytes from the $\gamma\delta$ CTCL lymphoma patient MF318

The $\gamma\delta$ T lymphoma cells of CTCL type were sourced from the public scRNAseq dataset of CTCL patient MF318 (GEO GSE173205, Methods), a 55 years old Caucasian female patient diagnosed with stage IIB CD30⁺ $\gamma\delta$ MF without large cell transformation [10]. Its $\gamma\delta$ T lymphocytes were digitally purified using score and gate by successively discarding the keratinocytes, melanocytes, myeloid, B, natural killer (NK), CD4 T, and finally CD8 T cells from the dataset. A total of 1,220 $\gamma\delta$ T cells were obtained. We previously produced a so-called ‘public’ differentiation trajectory of $\gamma\delta$ T cells from > 150 individuals’ blood and tissue samples [2]. Using the single-cell injector procedure (Methods, Figure S1), the ($n = 1,220$) $\gamma\delta$ T cells from the CTCL patient MF318 were injected into this reference. With ~20,000 cells distributed in 14 milestones from Tn to Temra cells, this trajectory represents the most exhaustive and resolutive map of $\gamma\delta$ T differentiation so far (Figure 1a). Together, these milestones still form a consistent and coherent continuum when the integrated dataset is represented by an alternative computational method such as UMAP (Figure 1b). Also, visualization in this UMAP of the trajectory pseudotime validated the previous sequence of differentiation milestones (Figure 1b). In UMAP, the $\gamma\delta$ T cells from the CTCL patient MF318 were embedded in all areas of the dataset, confirming their transcriptomic similarity to the reference $\gamma\delta$ T cells. Also, these cells encompassed both TCRV γ 9 and TCRV γ non9 $\gamma\delta$ T cell subsets (Figure 1d). The expression profile of a series of published marker genes [2, 21] in each milestone showed smooth profile transitions across the trajectory (Figure 1e). Based on expression intensity and percentage of expressing cells, the Tn marker genes typically encompass *CCR7*, *TCF7*, *LTB*, and *SELL*; Tcm genes include *ANXA1*, *PABPC1*, *IL7R*, *H3F3B*, *CD69*, *LYAR*, *CXCR4*, *KLRB1*, *NR4A2* and *FOS*, Tem genes comprise *S100A6*, *KLRD1*, *NKG7*, *CST7*, *PFN1*, *GZMM*, *GZMB*, *DUSP2*, *FTH1*, *CCL4*, and *IL2RG*, and Temra genes include *FCGR3A*, *S100A4*, *PRF1*, *GZMA*, *FGFBP2*, *GZMH*, and *KLRK1*. These profiles confirmed earlier reports [2, 21] depicting a progressive differentiation of type-1 cytotoxic functions along Tem and Temra stages, with the Temra cells detected here in both M13 and M14 instead of M14 only [2]. Few innate-like $\gamma\delta$ T cells were present in this integrated reference dataset, as *KLRB1* (encoding for CD161) was expressed by most of the late Tcm (M7) cells but *KLRK1* (encoding for NKG2A) and *TBX1* (encoding for PLZF1) by very few Tem (M13) cells. Fetal differentiation-derived type-3 effector $\gamma\delta$ T cells revealed by their *CCR6*, *RORC*, *IL23R*, and *DPP4* marker genes [21] were not abundant in the integrated reference, though clearly represented in most milestones (not shown).

Given the correspondence of the differentiation trajectory and UMAP visualizations of the integrated dataset, we investigated further the $\gamma\delta$ T cells from the CTCL patient MF318 with the higher resolution of pseudotimed trajectory maps.

Differentiation trajectory of the $\gamma\delta$ T and CD8 T cells from the patient MF318

Among the variants of CTCL, MF is depicted as a malignancy of skin-resident Tem cells, in contrast to leukemic CTCL which is composed of skin-recirculating malignant Tcm cells [9]. So to determine precisely the differentiation of the skin $\gamma\delta$ T cells from patient MF318, the ($n = 1,220$) $\gamma\delta$ T cells were analyzed by injection in the reference $\gamma\delta$ T pseudotimed trajectory. In parallel controls, ($n = 238$) CD8 T lymphocytes extracted from the same CTCL dataset were injected into their respective CD8 T reference differentiation trajectory [2]. These CD8 T cells encompassed a few Tn, Tcm, and early Tem cells, but no Temra (Figure 2). In contrast, the $\gamma\delta$ T cells displayed all stages of differentiation. When cells were stratified by patch or plaque origin, the CD8 T cells differentiation was similar in both cases. In contrast, the $\gamma\delta$ T cells from the patch were only Tn and early Tcm cells, while in the plaque, they comprised a few late Tcm and mostly Tem cells (Figure 2).




Figure 2. Differentiation of $\gamma\delta$ T and CD8 T lymphocytes from a $\gamma\delta$ CTCL patient MF318 skin dataset. The ($n = 238$) CD8 T (top) and ($n = 1,220$) $\gamma\delta$ T (bottom) cells digitally extracted from the scRNAseq dataset of MF318 patient skin are overlaid on their respective differentiation trajectory, specifying the patch or plaque tissue source. The respective reference trajectory and milestones are shown above for CD8 T cells (top) and $\gamma\delta$ T cells (bottom). $\gamma\delta$ T cell differentiation pseudotime scale: 0–5 for Tn, 5–20 for Tcm, 20–48 for Tem, 48–55 for Temra

These analyses unveiled a $\gamma\delta$ T cell-selective differentiation from Tcm to Tem upon the patch-to-plaque progression of patient MF318's skin lesions.

Hallmarks of the $\gamma\delta$ T cell subset from the skin infiltrate

By scoring various gene signatures and applying a classifier based on these scores (Methods), the above $\gamma\delta$ T cells were characterized for TCRV γ 9 or TCRV γ non9 subset, tissue-residency or recirculating, and exhaustion or functional cell states. These distinct features were then visualized simultaneously on the mapped $\gamma\delta$ T cells (Figure 3a). This showed that the TCRV γ non9 subset ($n = 1,189$ TCRV γ non9 cells vs. $n = 31$ TCRV γ 9 cells) was largely prominent among the skin $\gamma\delta$ T cells (Figure 3). Unexpectedly however, these TCRV γ non9 lymphocytes were in majority recirculating ($n = 723$ recirculating, $n = 466$ Ttrm), and their ($n = 167$) Tex cells were more often Ttrm ($n = 116$ Tex; 25% of the Ttrm) than recirculating lymphocytes ($n = 51$ Tex; 7% of the recirculating). The fewer TCRV γ 9 cells comprised ($n = 19$) recirculating cells including ($n = 2$) Tex and ($n = 12$) functional Ttrm.

There were evident changes during the patch-to-plaque progression concerning cell counts: the TCRV γ 9 cells remained unchanged and scarce in both samples ($n = 13$ cells in patch, $n = 18$ in plaque), while the TCRV γ non9 cells strongly increased ($n = 471$ cells in patch, $n = 718$ cells in plaque). This was a doubling of the cell counts for recirculating cells (patch: $n = 247$ Ttrm and $n = 224$ recirculating, plaque: $n = 219$ Ttrm and $n = 499$ recirculating). In the patch, the recirculating compartment of TCRV γ non9 lymphocytes comprised 18% Tn, 62% Tcm ($n = 139$ cells), 20% Tem, and 0% Temra cells, while in the plaque it comprised 0% Tn, 7% Tcm, 86% Tem ($n = 431$ cells), and 7% Temra (Figure 3b).




Figure 3. Functional hallmarks of skin $\gamma\delta$ T lymphocytes from patient MF318. a). The TCRV γ 9 (blue) and TCRV γ non9 (orange), as well as the Ttrm (cross) or non-Ttrm (circle), and the Tex or non-Tex hallmarks of cells among the $\gamma\delta$ T lymphocytes shown in Figure 1 are visualized overlaid on the same public trajectory of $\gamma\delta$ T lymphocyte differentiation. $\gamma\delta$ T cell differentiation pseudotime scale: 0–5 for Tn, 5–20 for Tcm, 20–48 for Tem; 48–55 for Temra; b). same as above focused on the circulating TCRV γ non9 cells only, by tissue source. The similarity of this panel with the global view (Figure 2) reflected the TCRV γ 9 cells ($n = 31$) scarcity among the total $\gamma\delta$ T cells ($n = 1,220$, Figure 2 bottom)

Thus the patch-to-plaque progression of the $\gamma\delta$ CTCL patient MF318 involved a Tcm proliferation and Tem differentiation of the TCRV γ non9 subset of skin $\gamma\delta$ T lymphocytes.

Hallmarks of the circulating TCRV γ non9 Tem cells

To further determine cellular hallmarks of the plaque $\gamma\delta$ T lymphocytes, we compared various pathway signatures between the circulating TCRV γ non9 $\gamma\delta$ T Tem cells (milestones M8–M12) and in their corresponding control cells ($n = 1,431$) from reference's healthy donors [1].

Several signatures appeared significantly enriched in the plaque Tem cells (Figure 4). Their most upregulated encompassed T cell activation signatures (graft-versus-host disease, type 1 diabetes, allograft rejection, autoimmune thyroid disease) and immune escape to cell cytotoxicity (protection from NK cell lysis, protein tyrosine kinase inhibition). Asthma and immunoglobulin E (IgE) binding corresponding to an allergic context were enriched in the plaque $\gamma\delta$ T cells, suggesting that some contact dermatitis could underlie this progression of lesions [22]. The 'viral ribonucleoprotein (RNP) complexes in the host cell nucleus' signature were also significantly upregulated which, together with significantly downregulated cytosolic DNA sensing, toll-like receptors (TLR), cytokine, and chemokine signalings, supported the hypothesis of a viral infection in CTCL [23]. By contrast, activities of several transcription factors [targets of early 2 factor (E2F), MYC, and the polycomb repressive complex 2-enhancer of zeste homolog 2 (PRC2-EZH2) and PRC1-BMI1] and all the main energetic pathways [glycolysis, oxidative phosphorylation, fatty acid (FA) metabolism] were significantly upregulated in the Tem TCRV γ non9 $\gamma\delta$ T cells from the plaque (Figure 4 right panel). Further comparisons of the same lymphocytes from patches to their respective controls unveiled that circulating Tem TCRV γ non9 $\gamma\delta$ T cells with the above signatures were less abundant but actually present in the earlier patches (Figure 4 left panel).




Figure 4. Most significant gene signatures of the skin circulating TCRV γ non9 Tem $\gamma\delta$ T cells (milestones M8–M13) relative to the same subset of correspondingly differentiated $\gamma\delta$ T cells ($n = 1,431$) from healthy donors. Left: patch–derived $\gamma\delta$ T cells vs. control cells; right: same analyses for plaque-derived $\gamma\delta$ T cells vs. control cells (color key: signature databases; P values from)

So the TCRV γ non9 $\gamma\delta$ T cell proliferation and differentiation-associated with the patch-plaque switch of patient MF318 involved a global evolution of their transcriptome profile.

Differentiation of the circulating TCRV γ non9 Tem CTCL cells

During the differentiation of control $\gamma\delta$ T lymphocytes from healthy individuals, there is no flagrant change in the expression level of the main energetic pathways (Figure S2). So here, we aimed at characterizing more precisely those skin recirculating Tem TCRV γ non9 $\gamma\delta$ T cells displaying increased levels of the above signatures. Plotting all the patient's $\gamma\delta$ T cells for both energetic pathways (sum of glycolysis, OXPHOS, and FA metabolism scores) vs. transcription factor activity (E2F targets) confirmed that some cells, more numerous in the plaque, had simultaneously up-regulated both signatures (Figure 5a). When selected for a focused analysis, these ($n = 342$) cells comprised 98% of TCRV γ non9 lymphocytes (Figure 5b). Their positioning on trajectories characterized a majority of Tcm cells in the patch and of effector cells in the plaque (Figure 5c). However, rare ($n = 8$) Tn cells from the patch also displayed this activated phenotype (Figure 5c). Finally, mapping the oxidative phosphorylation levels in ungated $\gamma\delta$ T cells from healthy controls and MF318 patch and plaque (not shown) confirmed that this activated phenotype of plaque TCRV γ non9 cells was not the mere consequence of normal $\gamma\delta$ T differentiation, consistent with their malignant state.

Hence, the MF318 patient's skin lesions encompass a sizeable subset of recirculating skin TCRV γ non9 $\gamma\delta$ T cells whose energetic and transcriptional profiles were above those of normal cells all along with their Tn, Tcm, and Tem differentiation, consistent with the malignant status of these MF skin-derived $\gamma\delta$ T cells [10].




Figure 5. Recirculating skin TCRV γ 9 Tem $\gamma\delta$ T cells with dually upregulated energetic and transcriptional profiles. a: Scatterplot of scores for the specified signatures (same as in Figure 3) of all the patch- and plaque-derived $\gamma\delta$ T cells; b: the gate of dual profiles-upregulating $\gamma\delta$ T cells; c: differentiation maps of the gated cells. Results per sample, gated cells (purple) overlaid to the reference trajectory (grey). $\gamma\delta$ T cell differentiation pseudotime scale: 0–5 for Tn, 5–20 for Tcm, 20–48 for Tem; 48–55 for Temra

Discussion

The separation of human $\gamma\delta$ T lymphocytes according to their differentiation stage has been instrumental to understand their different functions in the immune response to various challenges. Typically, this was done by flow cytometry analyses of cells surface markers that separate differentiation subsets and then ascribing molecular hallmarks and immune functions to these subsets. However, the mere split of any TCR-delineated $\gamma\delta$ T cell subset into four successive Tn, Tcm, Tem, and Temra stages based on cell surface phenotypes is well established but might mask some critical levels of information such as those from gene expression. The development of scRNAseq technologies provides us with visualizations of the transcriptomic-based cell transitions between differentiation stages with a far better resolution than ever before. This progress is not achieved by harnessing both the profiles of genes transcribed in each cell, but also by determining precisely each cell's relative position in a pseudotime-ordered collection of the same cell type ('reference dataset').

We had previously depicted the pseudotimed differentiation trajectory of human $\gamma\delta$ T lymphocytes from either TCRV γ 9TCRV δ 2 and TCRV γ non9TCRV δ 1 subset, and their subdivision into 14 discrete milestones [2]. Consistent with earlier reports [1, 21], the naive $\gamma\delta$ T lymphocytes encompass two stages M1 and M2 sharing graded expression levels of *LEF1* and *TCF7*, two genes encoding for Tn-typifying transcription factors [24, 25] together with those of the homing factors *CCR7* and *SELL* [26]. This finer subdivision of Tn $\gamma\delta$ T lymphocytes was not reported in earlier scRNAseq studies analyzing fewer cells [27]. The following five Tcm milestones include a smooth profile transitions from the M3 milestone as illustrated by the Tn-like gene *LTB*, to the following Tcm M4–M7 that display progressively reduced Tn gene but increasing levels of activation genes *FOS*, *IL7R*, *CD69*, *CD44*, and *CXCR4* genes. Such an ordering validated the original proposal of Tcm as a transitional status between true Tn and Tem [28] and also pinpoints the Tn cell differentiation-promoting *ANXA1* [29] and regulatory genes *NR4A2*, *PABPC1*, *H3F3B*, and *LYAR* as

Tcm-selective gene markers [21]. Following the Tcm but branching from the M5 milestone, 6 milestones of Tem stages reflected a cytotoxicity gene expression gradient (*NKG7*, *CST7*, *PFN1*, *GZMB*, *FCGR3A*, among others). During the M8–M12 Tem, the pleiotropic immune effector functions [30] were not consistently overlaid as the T-helper 1 (Th1) cytokine and cytolytic functions were rather sequentially tiled. The prototype of *Th1* gene encoding for interferon gamma (*IFNG*) peaked (M10–M11) before the cytotoxicity genes whose expression increased continuously along M8–M14. Both the perforin-encoding *PRF1* gene and the high-affinity receptor for antibody-dependent cell cytotoxicity *FCGR3A* peak at the Temra stage (M13–M14) [1, 31] constituting the endpoint of this type-1 cytotoxic differentiation. Presumably, the scarcity of innate-like $\gamma\delta$ T and fetal wave-derived type 3 effector cells found in the integrated reference dataset reflects its lack of neonatal or cord blood cells recently depicted elsewhere [21]. Overall, this trajectory clarified how $\gamma\delta$ T lymphocytes blend their innate programming and functional polarization [32] through temporal tiling. This trajectory also constitutes a reference roadmap onto which *ab extra* $\gamma\delta$ T cells from any additional scRNAseq datasets can now be positioned such as to identify their hallmarks. The $\gamma\delta$ T cells infiltrating human tumors, and those from blood or lung lesions of COVID-19 patients were characterized accordingly [3]. Likewise, mapping of $\gamma\delta$ T cells extracted from a human $\gamma\delta$ T cell lymphoma scRNAseq dataset had never been attempted, however, and the present study reports its successful use for characterizing CTCL of $\gamma\delta$ T lineage.

Our report shows that trajectory mappings can help to explore the cell-of-origin of a cancer cell type and its molecular transitions, beyond the more classic characterization of normal cell differentiation as currently reported [33]. Specifically, CTCL is a heterogeneous group of non-Hodgkin T cell lymphoma whose etiology remains ill-defined [34]. Among these, the $\gamma\delta$ CTCL constitutes an uncommon type of aggressive disease in which cell-of-origin depends on the tissue from which the lymphoma derives. Hepatosplenic and subcutaneous fat panniculitis-like $\gamma\delta$ T cell lymphoma develops from the TCRV γ 9V δ 2 subsets of cells while the $\gamma\delta$ T cell lymphomas arising from the epidermis and dermis rather develop from TCRV γ non9V δ 1 lymphocytes [4, 7, 35]. Given the prominent TCRV γ non9/TCRV δ 1 and TCRV γ 9/TCRV δ 2 cell surface TCR chain pairings of human $\gamma\delta$ T lymphocytes, the TCRV γ non9 cell differentiating while the skin patch evolves to plaque lesions suggests a cell-of-origin for the CTCL-like progression in this $\gamma\delta$ MF patient. At this point, however, whether this differentiating TCRV γ non9 $\gamma\delta$ T cell population homogeneously represents a truly malignant MF single clone or a mix with premalignant and/or non-malignant polyclonal TCRV γ non9 $\gamma\delta$ T cells remain undetermined. On the one hand, the original case report depicts this cell population as a single ‘malignant $\gamma\delta$ T cell clone’ [10]. On the other hand, TCRV γ non9 $\gamma\delta$ T cells are physiological skin-resident and the cells under study were from a thigh skin patch and plaque diagnosed as stage IIB CD30⁺ $\gamma\delta$ MF without large cell transformation [10]. Although next-generation sequencing of a single cell’s whole exomes would be necessary to formally detect whether-/which- plaque’s TCRV γ non9 $\gamma\delta$ T cells carry some of the known CTCL driver mutation(s) [7], this can not be done with the currently available scRNAseq dataset.

This study evidenced a TCRV γ non9-selective differentiation of a recirculating subset of skin $\gamma\delta$ T lymphocytes associated with MF disease progression. The non-random TCR chain usage of $\gamma\delta$ CTCL suggests common triggering antigens for TCRV γ non9TCRV δ 1 and TCRV γ 9TCRV δ 2 $\gamma\delta$ lymphomas [7]. Indeed, skin-colonizing *Staphylococcus aureus* can contribute to the pathogenesis of MF and Sezary syndrome (SS), notably through superantigens driving tumor cells proliferation [36]. More specific antigens for TCRV γ non9 cells such as CD1d-restricted lipids [7], histidyl-tNAsynthase, or butyrophilin-like 3-restricted antigens have been proposed [37–40], but the precise structure of antigens driving the T cell lymphomagenesis remain unidentified. This information is currently out of reach to approaches using scRNAseq, although a viral signature ‘viral RNP complex in the nucleus’ possibly suggesting undefined viral antigens was underpinned here by enrichment analysis (Figure 4).

Whatever the antigen, however, TCR stimulation of T lymphocytes drives their differentiation. Flow cytometry analyses of surface markers such as CCR7, CD27, and CD62L characterized MF as a malignancy of non-cytotoxic skin CD4 Tem cells, by contrast with SS that generally arises from a single transformed clone of CD4 Tcm recirculating cells [41, 42]. Since Tcm is a stage more proliferative and recirculating between skin and blood, Tcm cells are more prone to lead to the dissemination of aggressive SS with high phenotypic heterogeneity [43–46]. Here, unveiling that skin patch Tn and Tcm $\gamma\delta$ T cells differentiate into Tem Trm cells

when lesion switched to plaque confirms the prominence of skin-resident Tem cells in MF lesions [9]. This also suggests that among skin TCRV γ non9 $\gamma\delta$ T cells, the Tcm are more prone than Tem to recirculate in blood [47].

Aside from the TCRV γ non9 $\gamma\delta$ T cell differentiation associated with progression of the MF CTCL, the finding here is that the other subsets of cytolytic skin T lymphocytes, namely CD8 T and TCRV γ 9 $\gamma\delta$ T cells, remained unaffected by this progression (Figures 2 and 3) is puzzling and confirms further the correlated differentiation of $\gamma\delta$ T and CD8 T TILs in human cancers [2]. Whatever the disease stage, the skin-infiltrating TCRV γ 9 $\gamma\delta$ T lymphocytes represented a minority of the TILs from this CTCL sample, presumably as blood-borne cells, and they did not differentiate while the disease progressed. This might reflect their lack of genuine tropism for this epithelial tissue in nearly physiological conditions, or alternatively that the TCRV γ non9 $\gamma\delta$ T MF cells did not up-regulate phosphoantigens/butyrophilins prone to activate the blood TCRV γ 9 $\gamma\delta$ T lymphocytes. Second, these malignant MF cells had upregulated several pathways providing an immune escape to NK cell cytotoxicity, apparently prior to detectable activation of the TILs (Figure 3). Hence in this MF patient, the lesion progressed in a landscape without change of cell counts or phenotype from neighboring cytolytic TILs, while the MF cells evolved protection from immune attack. This landscape was consistent with earlier studies of B cell non-Hodgkin's lymphoma (B-NHLs) which upregulate immune escape pathways before TIL cell activation [48]. Finally, the JAK/signal transducers and activators of transcription (STAT), mitogen-activated protein kinases (MAPK), MYC, and chromatin modification pathways which are mutated in most $\gamma\delta$ CTCL [7] corresponded to the upregulated gene signature profile found here in the MF318 patient's plaque cells. These cells also upregulated both energetic pathways through a non-physiological metabolic decoupling classically found in malignant cells. So, the TCRV γ non9 Tem cells of skin-resident $\gamma\delta$ T lymphocytes display a phenotype merging immune-escape, high energetic supply, and elevated transcriptional activities, recapitulating the hallmarks of cancer cells. Beyond confirming and extending the original identification of a $\gamma\delta$ CTCL in an MF patient [10], our study provides an important resource for hematological cancer research. Beyond, it suggests that implementing the therapeutic targeting of $\gamma\delta$ CTCL with small molecule inhibitors of energetic metabolism and $\gamma\delta$ T cell-based cancer immunotherapies represent promising approaches for these treatment-refractory diseases.

Abbreviations

CTCL: cutaneous T-cell lymphoma

GEO: Gene Expression Omnibus

MF: mycosis fungoides

MST: minimum spanning tree

NK: natural killer

scRNAseq: single-cell RNA sequencing

SS: Sezary syndrome

Tcm: central memory T cells

TCR: T-cell receptor

TCRV γ 9: T-cell receptor variable chain γ 9

Tem: effector memory T cells

Temra: CD45Ra⁺ effector memory T cells

Tex: exhausted T cell

TIL: tumor-infiltrating lymphocyte

Tn: naive T cells

Ttrm: tissue resident memory T cell

UMAP: uniform manifold approximation and projection

Supplementary materials

The supplementary Figures for this article are available at: https://www.explorationpub.com/uploads/Article/file/100344_sup_1.pdf. The supplementary Tables for this article are available at: https://www.explorationpub.com/uploads/Article/file/100344_sup_2.tsv and https://www.explorationpub.com/uploads/Article/file/100344_sup_3.tsv.

Declarations

Acknowledgments

We thank Pierre Brousset, Jean Philippe Merliot, and CRCT collaborators for support and critical discussions.

Author contributions

JJF and JPC conceived and designed the study, JPC conceived methods, processed and performed bioinformatic data analyses, JJF and JPC generated figures, and wrote the manuscript. MP and FP conceived algorithms. CL, SB and JJF supervised the study and all authors wrote the paper. All authors contributed to manuscript revision, read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Further information and reasonable requests for the integrated (cell, gene, hallmarks) matrix of extracted $\gamma\delta$ T should be directed to Jean-Jacques Fournie (jean-jacques.fournie@inserm.fr) or Juan-Pablo Cerapio (juan-pablo.cerapio-arroyo@inserm.fr).

Funding

This work was supported in part by institutional grants from the Institut National de la Santé et de la Recherche Médicale (INSERM), the Université Toulouse III-Paul Sabatier, the Centre National de la Recherche Scientifique (CNRS); Laboratoire d'Excellence Toulouse Cancer (TOUCAN-2) under grant contract ANR11-LABX, the Fondation ARC under grant contract PGA1-RF2019-0208691; Institut Universitaire du Cancer de Toulouse-Oncopole under contract CIEL. This work was granted access to the HPC resources of CALMIP supercomputing center under allocation 2020-T19001. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

© The Author(s) 2022.

References

1. Pizzolato G, Kaminski H, Tosolini M, Franchini DM, Pont F, Martins F, et al. Single-cell RNA sequencing unveils the shared and the distinct cytotoxic hallmarks of human TCRV δ 1 and TCRV δ 2 $\gamma\delta$ T lymphocytes. *Proc Natl Acad Sci U S A*. 2019;116:11906–15.

2. Cerapio JP, Perrier M, Balança CC, Gravelle P, Pont F, Devaud C, et al. Phased differentiation of $\gamma\delta$ T and T CD8 tumor-infiltrating lymphocytes revealed by single-cell transcriptomics of human cancers. *Oncoimmunology*. 2021;10:1939518.
3. Cerapio JP, Perrier M, Pont F, Tosolini M, Laurent C, Bertani S, et al. Single-cell RNAseq profiling of human $\gamma\delta$ T lymphocytes in virus-related cancers and COVID-19 disease. *Viruses*. 2021;13:2212.
4. Przybylski GK, Wu H, Macon WR, Finan J, Leonard DG, Felgar RE, et al. Hepatosplenic and subcutaneous panniculitis-like gamma/delta T cell lymphomas are derived from different Vdelta subsets of gamma/delta T lymphocytes. *J Mol Diagn*. 2000;2:11–9.
5. Foppoli M, Ferreri AJ. Gamma-delta t-cell lymphomas. *Eur J Haematol*. 2015;94:206–18.
6. Merrill ED, Agbay R, Miranda RN, Aung PP, Tetzlaff MT, Young KH, et al. Primary cutaneous T-cell lymphomas showing gamma-delta ($\gamma\delta$) phenotype and predominantly epidermotropic pattern are clinicopathologically distinct from classic primary cutaneous $\gamma\delta$ T-cell lymphomas. *Am J Surg Pathol*. 2017;41:204–15.
7. Daniels J, Doukas PG, Escala MEM, Ringbloom KG, Shih DJH, Yang J, et al. Cellular origins and genetic landscape of cutaneous gamma delta T cell lymphomas. *Nat Commun*. 2020;11:1806.
8. Torres-Cabala CA, Huen A, Iyer SP, Miranda RN. Gamma/delta phenotype in primary cutaneous T-cell lymphomas and lymphoid proliferations: challenges for diagnosis and classification. *Surg Pathol Clin*. 2021;14:177–94.
9. Clark RA, Watanabe R, Teague JE, Schlapbach C, Tawa MC, Adams N, et al. Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. *Sci Transl Med*. 2012;4:117ra7.
10. Rindler K, Jonak C, Alkon N, Thaler FM, Kurz H, Shaw LE, et al. Single-cell RNA sequencing reveals markers of disease progression in primary cutaneous T-cell lymphoma. *Mol Cancer*. 2021;20:124.
11. Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM 3rd, et al. Comprehensive integration of single-cell data. *Cell*. 2019;177:1888–902.e21.
12. McInnes L, Healy J, Melville J. Umap: uniform manifold approximation and projection for dimension reduction. *ArXiv [Preprint]*. 2018 arXiv:1802.03426 [posted 2018 Feb 9; revised 2018 Dec6; revised 2020 Sep18; cited 2022 Mar 01]. Available from: <https://arxiv.org/abs/1802.03426>
13. Pont F, Tosolini M, Fournié JJ. Single-cell signature explorer for comprehensive visualization of single cell signatures across scRNA-seq datasets. *Nucleic Acids Res*. 2019;47:e133.
14. Chihara N, Madi A, Kondo T, Zhang H, Acharya N, Singer M, et al. Induction and transcriptional regulation of the co-inhibitory gene module in T cells. *Nature*. 2018;558:454–9.
15. Alfei F, Kanev K, Hofmann M, Wu M, Ghoneim HE, Roelli P, et al. TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection. *Nature*. 2019;571:265–9.
16. Khan O, Giles JR, McDonald S, Manne S, Ngiow SF, Patel KP, et al. TOX transcriptionally and epigenetically programs CD8⁺ T cell exhaustion. *Nature*. 2019;571:211–8.
17. Tosolini M, Algans C, Pont F, Ycart B, Fournié JJ. Large-scale microarray profiling reveals four stages of immune escape in non-Hodgkin lymphomas. *Oncoimmunology*. 2016;5:e1188246.
18. Balança CC, Scarlata CM, Michelas M, Devaud C, Sarradin V, Franchet C, et al. Dual relief of T-lymphocyte proliferation and effector function underlies response to PD-1 blockade in epithelial malignancies. *Cancer Immunol Res*. 2020;8:869–82.
19. Kumar BV, Ma W, Miron M, Granot T, Guyer RS, Carpenter DJ, et al. Human tissue-resident memory T cells are defined by core transcriptional and functional signatures in lymphoid and mucosal sites. *Cell Rep*. 2017;20:2921–34.
20. Wu TD, Madireddi S, de Almeida PE, Banchereau R, Chen YJ, Chitre AS, et al. Peripheral T cell expansion predicts tumour infiltration and clinical response. *Nature*. 2020;579:274–8.

21. Tan L, Fichtner AS, Bruni E, Odak I, Sandrock I, Bubke A, et al. A fetal wave of human type 3 effector $\gamma\delta$ cells with restricted TCR diversity persists into adulthood. *Sci Immunol*. 2021;6:eabf0125.
22. Tilakaratne D, Sidhu S. Heavy metal (monoclonal) bands: a link between cutaneous T-cell lymphoma and contact allergy to potassium dichromate, nickel and cobalt? *Australas J Dermatol*. 2015;56:59–63.
23. Whittemore AS, Holly EA, Lee IM, Abel EA, Adams RM, Nickoloff BJ, et al. Mycosis fungoides in relation to environmental exposures and immune response: a case-control study. *J Natl Cancer Inst*. 1989;81:1560–7.
24. Szabo PA, Levitin HM, Miron M, Snyder ME, Senda T, Yuan J, et al. Single-cell transcriptomics of human T cells reveals tissue and activation signatures in health and disease. *Nat Commun*. 2019;10:4706.
25. Xing S, Li F, Zeng Z, Zhao Y, Yu S, Shan Q, et al. Tcf1 and Lef1 transcription factors establish CD8⁺ T cell identity through intrinsic HDAC activity. *Nat Immunol*. 2016;17:695–703.
26. Girard JP, Moussion C, Förster R. HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes. *Nat Rev Immunol*. 2012;12:762–73.
27. Anvari S, Watkin L, Rajapakshe K, Hassan O, Schuster K, Coarfa C, et al. Memory and naïve gamma delta regulatory T-cell gene expression in the first 24-weeks of peanut oral immunotherapy. *Clin Immunol*. 2021;230:108820.
28. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. *Annu Rev Immunol*. 2004;22:745–63.
29. D'Acquisto F, Merghani A, Lecona E, Rosignoli G, Raza K, Buckley CD, et al. Annexin-1 modulates T-cell activation and differentiation. *Blood*. 2007;109:1095–102.
30. Silva-Santos B, Mensurado S, Coffelt SB. $\gamma\delta$ T cells: pleiotropic immune effectors with therapeutic potential in cancer. *Nat Rev Cancer*. 2019;19:392–404.
31. Angelini DF, Borsellino G, Poupot M, Diamantini A, Poupot R, Bernardi G, et al. Fc γ RIII discriminates between 2 subsets of V γ 9V δ 2 effector cells with different responses and activation pathways. *Blood*. 2004;104:1801–7.
32. Bonneville M, O'Brien RL, Born WK. Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity. *Nat Rev Immunol*. 2010;10:467–78.
33. Gros A, Merlio JP. Single-cell trajectories in Sézary syndrome. *Blood*. 2021;138:1384–6.
34. de Leval L, Gaulard P. Cellular origin of T-cell lymphomas. *Blood*. 2014;123:2909–10.
35. Gaulard P, de Leval L. Pathology of peripheral T-cell lymphomas: where do we stand? *Semin Hematol*. 2014;51:5–16.
36. Fujii K. Pathogenesis of cutaneous T cell lymphoma: involvement of *Staphylococcus aureus*. *J Dermatol*. 2022;49:202–9.
37. Le Nours J, Gherardin NA, Ramarathinam SH, Awad W, Wiede F, Gully BS, et al. A class of $\gamma\delta$ T cell receptors recognize the underside of the antigen-presenting molecule MR1. *Science*. 2019;366:1522–7.
38. Pellicci DG, Uldrich AP. Unappreciated diversity within the pool of CD1d-restricted T cells. *Semin Cell Dev Biol*. 2018;84:42–7.
39. Van Rhijn I, van Berlo T, Hilmenyuk T, Cheng TY, Wolf BJ, Tatituri RV, et al. Human autoreactive T cells recognize CD1b and phospholipids. *Proc Natl Acad Sci U S A*. 2016;113:380–5.
40. Uldrich AP, Le Nours J, Pellicci DG, Gherardin NA, McPherson KG, Lim RT, et al. CD1d-lipid antigen recognition by the $\gamma\delta$ TCR. *Nat Immunol*. 2013;14:1137–45.
41. Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. *Blood*. 2010;116:767–71.
42. Kirsch IR, Watanabe R, O'Malley JT, Williamson DW, Scott LL, Elco CP, et al. TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL. *Sci Transl Med*. 2015;7:308ra158.
43. Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. *Blood*. 2019;133:1703–14.

44. Buus TB, Willerslev-Olsen A, Fredholm S, Blümel E, Nastasi C, Gluud M, et al. Single-cell heterogeneity in Sézary syndrome. *Blood Adv.* 2018;2:2115–26.
45. Roelens M, Delord M, Ram-Wolff C, Marie-Cardine A, Alberdi A, Maki G, et al. Circulating and skin-derived Sézary cells: clonal but with phenotypic plasticity. *Blood.* 2017;130:1468–71.
46. Borchering N, Voigt AP, Liu V, Link BK, Zhang W, Jabbari A. Single-cell profiling of cutaneous T-cell lymphoma reveals underlying heterogeneity associated with disease progression. *Clin Cancer Res.* 2019;25:2996–3005.
47. Clark RA. Resident memory T cells in human health and disease. *Sci Transl Med.* 2015;7:269rv1.
48. Laurent C, Charmpi K, Gravelle P, Tosolini M, Franchet C, Ysebaert L, et al. Several immune escape patterns in non-Hodgkin's lymphomas. *Oncoimmunology.* 2015;4:e1026530.